| Exclusion Criteria: | 1) Prior exposure to >3 cycles of lenalidomide
2) Exposure to lenalidomide within the last 30 days
3) Prior history of leukemia or aplastic anemia
4) Prior history of stem cell transplantation
5) Prior malignancy (other than in situ cervical cancer or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for >/= 3 years before randomization
6) Active or uncontrolled infections
7) Unstable angina, congestive heart failure [NYHA > class II], uncontrolled hypertension [diastolic > 100 mmHg], uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction
8) History of arterial thrombosis ( eg, stroke or transient ischemic attack) in the past year
9) History of venous thrombosis in the past year
10) Received IL-11 within 4 weeks of screening
11) Less than 4 weeks since receipt of any investigational drug or device
12) Have previously received any other thrombopoietic growth factor
13) Subject is pregnant (eg, positive HCG test) or is breast-feeding.
14) Subject of reproductive potential who are not using adequate contraceptive precautions in the judgment of the investigator.
15) Subject has known hypersensitivity to any recombinant E coli-derived product (eg, InfergenŽ, NeupogenŽ, Somatropin, and Actimmune).
16) Subject previously has enrolled in this study
17) Subject will not be available for follow-up assessment.
18) Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures. |